A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Eliem Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 94,900 shares of ELYM stock, worth $390,039. This represents 0.0% of its overall portfolio holdings.

Number of Shares
94,900
Previous 114,000 16.75%
Holding current value
$390,039
Previous $468,000 16.67%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 14, 2025

SELL
N/A
-19,100 Reduced 16.75%
94,900 $390,000
Q1 2025

May 15, 2025

BUY
N/A
2,300 Added 2.06%
114,000 $468,000
Q4 2024

Feb 14, 2025

BUY
$4.11 - $5.42 $459,087 - $605,414
111,700 New
111,700 $459,000

Others Institutions Holding ELYM

About Eliem Therapeutics, Inc.


  • Ticker ELYM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,567,700
  • Market Cap $109M
  • Description
  • Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase II...
More about ELYM
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.